Evidence map›Paper›PMID 38033777›Full record

ArticleFrontiers in neurology2023

MiR-324-5p inhibition after intrahippocampal kainic acid-induced

Amanda M McGann, Grace C Westerkamp, Alisha Chalasani, Cole S K Danzer, Emma V Parkins, Valerine Rajathi, Paul S Horn, Ernest V Pedapati, Durgesh Tiwari, Steve C Danzer and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Amanda M McGannMedical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Grace C WesterkampDivision of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Alisha ChalasaniDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Cole S K DanzerDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Emma V ParkinsNeuroscience Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Valerine RajathiDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Paul S HornDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Ernest V PedapatiDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Durgesh TiwariDivision of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Steve C DanzerMedical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Christina GrossMedical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati Medical Center · US

Funding

PREDOCTORAL TRAINING PROGRAM IN THE NEUROSCIENCEST32NS007453 · NINDS · UNIVERSITY OF CINCINNATI · PI HERMAN, JAMES P · 1997 to 2025
$4.0M
Functional analysis of the microRNA-induced silencing complex in epilepsyR01NS107453 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI GROSS, CHRISTINA · 2020 to 2024
$1.9M
MicroRNA-mediated silencing of the Kv4.2 complex in epilepsyR01NS092705 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI GROSS, CHRISTINA · 2016 to 2020
$1.8M
Cell type-specific functions of microRNA in epilepsyR21NS126740 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI GROSS, CHRISTINA · 2022 to 2023
$437k
NINDS NIH HHS R01 NS092705NINDS NIH HHS R01 NS107453NINDS NIH HHS R21 NS126740NINDS NIH HHS T32 NS007453
6 · The paper itself

Abstract

Background: Acquired epilepsies are caused by an initial brain insult that is followed by epileptogenesis and finally the development of spontaneous recurrent seizures. The mechanisms underlying epileptogenesis are not fully understood. MicroRNAs regulate mRNA translation and stability and are frequently implicated in epilepsy. For example, antagonism of a specific microRNA, miR-324-5p, before brain insult and in a model of chronic epilepsy decreases seizure susceptibility and frequency, respectively. Here, we tested whether antagonism of miR-324-5p during epileptogenesis inhibits the development of epilepsy. Methods: We used the intrahippocampal kainic acid (IHpKa) model to initiate epileptogenesis in male wild type C57BL/6 J mice aged 6-8 weeks. Twenty-four hours after IHpKa, we administered a miR-324-5p or scrambled control antagomir intracerebroventricularly and implanted cortical surface electrodes for EEG monitoring. EEG data was collected for 28 days and analyzed for seizure frequency and duration, interictal spike activity, and EEG power. Brains were collected for histological analysis. Results: Histological analysis of brain tissue showed that IHpKa caused characteristic hippocampal damage in most mice regardless of treatment. Antagomir treatment did not affect latency to, frequency, or duration of spontaneous recurrent seizures or interictal spike activity but did alter the temporal development of frequency band-specific EEG power. Conclusion: These results suggest that miR-324-5p inhibition during epileptogenesis induced by

Indexed as

EEGepilepsyepileptogenesiskainic acidmicroRNA

Identifiers

PMID38033777
PMCPMC10687438
OpenAlexW4388723132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.